Insulet Corporation (NASDAQ:PODD – Get Free Report) has earned an average recommendation of “Hold” from the twenty-six ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $184.33.
Several analysts have issued reports on PODD shares. Jefferies Financial Group reissued a “buy” rating and set a $200.00 price target on shares of Insulet in a report on Wednesday, November 4th. Royal Bank Of Canada boosted their price objective on Insulet from $160.00 to $180.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Raymond James Financial reissued an “outperform” rating and issued a $180.00 target price on shares of Insulet in a report on Thursday, August 6th. Canaccord Genuity Group decreased their target price on shares of Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Finally, Robert W. Baird downgraded shares of Insulet from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $200.00 to $158.00 in a report on Friday.
Check Out Our Latest Analysis on PODD
Insulet Price Performance
Insulet (NASDAQ:PODD – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40. The business had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The firm’s quarterly revenue was up 19.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.24 earnings per share. On average, sell-side analysts expect that Insulet will post 6.76 earnings per share for the current year.
Institutional Investors Weigh In On Insulet
Several large investors have recently bought and sold shares of PODD. Elevation Wealth Partners LLC grew its position in Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 104 shares in the last quarter. Stance Capital LLC increased its stake in Insulet by 100.0% during the third quarter. Stance Capital LLC now owns 200 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 100 shares during the last quarter. Activest Wealth Management raised its position in Insulet by 186.3% during the third quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 149 shares during the period. WPG Advisers LLC raised its position in Insulet by 169.3% during the third quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 171 shares during the period. Finally, State of Wyoming raised its position in Insulet by 34.6% during the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after purchasing an additional 73 shares during the period.
Insulet Company Profile
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
Further Reading
- Five stocks we like better than Insulet
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
